WESTLAKE VILLAGE, Calif., Sept. 07, 2017 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) announced today the
company’s support for Hurricane Harvey victims with a donation of Afrezza® (insulin human) Inhalation Powder. The donation will be
shipped this week to Insulin for Life USA, Inc., a not-for-profit entity whose purpose is to aid those living with diabetes by
supplying life-saving insulin and other disease management supplies in times of need. Insulin for Life USA, Inc., The American
Diabetes Association, and JDRF have partnered to ensure that donated diabetic supplies get to shelters and county health leaders in
the affected areas as soon as possible.
“In times of crisis, many of us rely on our good health to help us get to better days,” said Michael Castagna, CEO of MannKind
Corporation. “Among the millions of residents impacted by Hurricane Harvey are people who must manage their diabetes to maintain
good health – but are separated by circumstance from their supplies. Extending a helping hand is consistent with our company’s
values, and simply the right thing to do.”
Available through prescription only, Afrezza® is a rapid-acting inhaled insulin used to improve glycemic control in adults with
diabetes. MannKind has authorized over 27,000 cartridges of insulin to be donated to Insulin for Life USA. For more information,
including important safety information, on Afrezza®, visit www.afrezza.com.
“When it comes to rebuilding a life following a major event like Hurricane Harvey, things rarely go according to schedule,” said
Castagna. “We hope that our support provides some relief to those in need during such a challenging time.”
About MannKind Corporation
MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) focuses on the development and commercialization of inhaled therapeutic
products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing
Afrezza® (insulin human) inhalation powder, the Company's first FDA approved product, in the United States, where it is available
by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art
manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S.
For further information, visit www.mannkindcorp.com.
Company Contact: Rose Alinaya SVP, Investor Relations 818-661-5000 ir@mannkindcorp.com
